UK Issues Allergy Warning Over Pfizer/BioNTech Vaccine

UK Issues Allergy Warning Over Pfizer-BioNTech Vaccine
A nurse prepares to administer the Pfizer-BioNTech COVID-19 vaccine at Guy’s Hospital in London, on December 8, 2020. Britain on December 8. Frank Augstein / POOL / AFP

British health officials has on Wednesday warned that anyone with a history of significant allergic reactions should not received the Pfizer/BioNTech COVID-19 vaccine for the time being.

The warning came after two members of the state-run National Health Service who were among the first to receive the vaccine on Tuesday suffered allergic reactions and needed treatment.

National Health Service (NHS) England medical director, Stephen Powis said both people, who had a history of reactions, were now recovering well.

He added that Independent Medicines and Healthcare products Regulatory Agency (MHRA) has now advised that “people with a significant history of allergic reactions do not receive this vaccination” as a precaution.

According to MHRA, “significant” allergic reactions include those to medicines, food or vaccines.

Read Also: 90-Year-Old Woman, Margaret Keenan Becomes First In UK To Receive Pfizer/BioNTech COVID-19 Vaccine

Thousands of Britons became the first in the Western world to receive an approved COVID-19 vaccine on Tuesday as NHS began the biggest vaccination drive since it was created in 1948.

The vaccine is administered in two doses, 21 days apart. The over-80s, health and social care staff are first in line to get the jab in the national rollout.

Britain has received some 800,000 doses of the vaccine in the first batch of an order of 40 million. Up to four million doses are expected by the end of December.

Read Also: Queen Elizabeth And Prince Philip To Get UK-Approved COVID-19 Vaccine In Weeks

On Tuesday, Pfizer chief executive, Albert Bourla said he understood global concerns about the speed with which pharmaceutical companies have produced vaccines against COVID-19 but insisted no corners were cut.

During a virtual media briefing in Geneva, Switzerland, he expressed that the vaccine had been tested “in the exact same way as we are testing any vaccine that is circulating out there”.

Pfizer said MHRA had told it of the allergic reactions but said during phase 3 trials of more than 40,000 people, the vaccine was “generally well-tolerated with no serious safety concerns” reported.

Via AFP.

Leave A Reply

Your email address will not be published.